JP2017507181A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017507181A5 JP2017507181A5 JP2016570199A JP2016570199A JP2017507181A5 JP 2017507181 A5 JP2017507181 A5 JP 2017507181A5 JP 2016570199 A JP2016570199 A JP 2016570199A JP 2016570199 A JP2016570199 A JP 2016570199A JP 2017507181 A5 JP2017507181 A5 JP 2017507181A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- protein
- uspa2
- immunogenic composition
- vaccine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461943909P | 2014-02-24 | 2014-02-24 | |
| US61/943,909 | 2014-02-24 | ||
| US201461946932P | 2014-03-03 | 2014-03-03 | |
| US201461946937P | 2014-03-03 | 2014-03-03 | |
| US61/946,932 | 2014-03-03 | ||
| US61/946,937 | 2014-03-03 | ||
| PCT/IB2015/051308 WO2015125118A1 (en) | 2014-02-24 | 2015-02-20 | Uspa2 protein constructs and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017507181A JP2017507181A (ja) | 2017-03-16 |
| JP2017507181A5 true JP2017507181A5 (enExample) | 2018-04-05 |
| JP6585085B2 JP6585085B2 (ja) | 2019-10-02 |
Family
ID=52629643
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016570199A Expired - Fee Related JP6585085B2 (ja) | 2014-02-24 | 2015-02-20 | Ｕｓｐａ２タンパク質構築物およびそれらの使用 |
Country Status (28)
| Country | Link |
|---|---|
| US (3) | US10040832B2 (enExample) |
| EP (2) | EP3110438B1 (enExample) |
| JP (1) | JP6585085B2 (enExample) |
| KR (1) | KR102515835B1 (enExample) |
| CN (2) | CN111499701A (enExample) |
| AU (1) | AU2015220369B2 (enExample) |
| BE (1) | BE1022345A9 (enExample) |
| BR (1) | BR112016019525B1 (enExample) |
| CA (1) | CA2939862C (enExample) |
| CY (2) | CY1121535T1 (enExample) |
| DK (2) | DK3110438T3 (enExample) |
| EA (1) | EA034352B1 (enExample) |
| ES (2) | ES2899300T3 (enExample) |
| HR (2) | HRP20211926T1 (enExample) |
| HU (2) | HUE057505T2 (enExample) |
| IL (1) | IL246994B (enExample) |
| LT (2) | LT3110438T (enExample) |
| ME (1) | ME03335B (enExample) |
| MX (1) | MX376079B (enExample) |
| PL (2) | PL3498292T3 (enExample) |
| PT (2) | PT3110438T (enExample) |
| RS (2) | RS58451B1 (enExample) |
| SG (1) | SG11201606272PA (enExample) |
| SI (2) | SI3110438T1 (enExample) |
| SM (2) | SMT201900166T1 (enExample) |
| TW (1) | TW201620927A (enExample) |
| UY (1) | UY36006A (enExample) |
| WO (1) | WO2015125118A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201620927A (zh) * | 2014-02-24 | 2016-06-16 | 葛蘭素史密斯克藍生物品公司 | Ｕｓｐａ２蛋白質構築體及其用途 |
| GB201621686D0 (en) | 2016-12-20 | 2017-02-01 | Glaxosmithkline Biologicals Sa | Novel methods for inducing an immune response |
| CA3057778A1 (en) * | 2017-03-31 | 2018-10-04 | Glaxosmithkline Biologicals Sa | Immunogenic composition, use and method of treatment |
| WO2018178265A1 (en) | 2017-03-31 | 2018-10-04 | Glaxosmithkline Intellectual Property Development Limited | Immunogenic composition, use and method of treatment |
| FR3066920A1 (fr) | 2017-05-30 | 2018-12-07 | Glaxosmithkline Biologicals S.A. | Nouveaux procedes de fabrication d'un adjuvant |
| CA3072018A1 (en) | 2017-08-14 | 2019-02-21 | Glaxosmithkline Biologicals Sa | Methods of boosting immune responses |
| JP2021504424A (ja) | 2017-12-01 | 2021-02-15 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | サポニン精製 |
| GB201803692D0 (en) * | 2018-03-08 | 2018-04-25 | Glaxosmithkline Biologicals Sa | Immunogenic composition |
| EP3833382A1 (en) | 2018-08-07 | 2021-06-16 | GlaxoSmithKline Biologicals S.A. | Processes and vaccines |
| CN112912097A (zh) * | 2018-08-23 | 2021-06-04 | 葛兰素史密丝克莱恩生物有限公司 | 免疫原性蛋白和组合物 |
| WO2020109365A1 (en) | 2018-11-29 | 2020-06-04 | Glaxosmithkline Biologicals Sa | Methods for manufacturing an adjuvant |
| US20220221455A1 (en) | 2019-04-18 | 2022-07-14 | Glaxosmithkline Biologicals Sa | Antigen binding proteins and assays |
| BR112021024363A2 (pt) | 2019-06-05 | 2022-03-22 | Glaxosmithkline Biologicals Sa | Purificação de saponina |
| JP2022543264A (ja) * | 2019-08-05 | 2022-10-11 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | プロテインｄポリペプチドを含む組成物を調製するプロセス |
| EP4010014A1 (en) | 2019-08-05 | 2022-06-15 | GlaxoSmithKline Biologicals S.A. | Immunogenic composition |
| US20230266317A1 (en) | 2019-09-11 | 2023-08-24 | Glaxosmithkline Biologicals Sa | Antigen binding protein and assays |
| EP4294433A1 (en) | 2021-02-22 | 2023-12-27 | GlaxoSmithKline Biologicals SA | Immunogenic composition, use and methods |
| EP4558170A1 (en) | 2022-07-19 | 2025-05-28 | GlaxoSmithKline Biologicals S.A. | Continuous process for vaccine production |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| SE466259B (sv) | 1990-05-31 | 1992-01-20 | Arne Forsgren | Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal |
| NZ253137A (en) | 1992-06-25 | 1996-08-27 | Smithkline Beecham Biolog | Vaccine comprising antigen and/or antigenic composition, qs21 (quillaja saponaria molina extract) and 3 de-o-acylated monophosphoryl lipid a. |
| EP0689454B2 (en) | 1993-03-23 | 2005-02-23 | SMITHKLINE BEECHAM BIOLOGICALS s.a. | Vaccine compositions containing 3-o deacylated monophosphoryl lipid a |
| GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
| DE69535905D1 (de) | 1994-07-15 | 2009-02-26 | Coley Pharm Group Inc | Immunomodulatorische Oligonukleotide |
| UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
| ATE497004T1 (de) * | 1996-12-20 | 2011-02-15 | Univ Texas | Moraxella catarrhalis antigene uspa1 und uspa2 |
| JP2004509970A (ja) | 2000-09-26 | 2004-04-02 | ハイブリドン・インコーポレイテッド | 位置的化学変化による免疫刺激オリゴヌクレオチドアナログの免疫刺激活性の調節 |
| WO2002083710A2 (en) * | 2001-04-13 | 2002-10-24 | Wyeth Holdings Corporation | Removal of bacterial endotoxin in a protein solution by immobilized metal affinity chromatography |
| AU2002355197A1 (en) * | 2001-07-27 | 2003-02-17 | Chiron Srl | Meningococcus adhesins nada, app and orf 40 |
| WO2003035836A2 (en) | 2001-10-24 | 2003-05-01 | Hybridon Inc. | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends |
| UA95456C2 (ru) * | 2005-08-10 | 2011-08-10 | Арне Форсгрен Аб | Взаимодействие moraxella catarrhalis с эпителиальными клетками, внеклеточными матриксными белками и системой комплемента |
| US8092811B2 (en) * | 2005-08-10 | 2012-01-10 | Arne Forsgren Ab | Interaction of Moraxella catarrhalis with epithelial cells, extracellular matrix proteins and the complement system |
| SG10201600336RA (en) * | 2006-01-17 | 2016-02-26 | Arne Forsgren | A novel surface exposed haemophilus influenzae protein (protein e; pe) |
| TW201302779A (zh) | 2011-04-13 | 2013-01-16 | Glaxosmithkline Biolog Sa | 融合蛋白質及組合疫苗 |
| JP2014516028A (ja) * | 2011-05-11 | 2014-07-07 | リースベック ヘルスケア スウェーデン アクティエボラーグ | ラミニン及びビトロネクチン結合特性を有するタンパク質ｆ−新規インフルエンザ菌付着因子 |
| TW201620927A (zh) * | 2014-02-24 | 2016-06-16 | 葛蘭素史密斯克藍生物品公司 | Ｕｓｐａ２蛋白質構築體及其用途 |
-
2015
- 2015-02-17 TW TW104105745A patent/TW201620927A/zh unknown
- 2015-02-20 HR HRP20211926TT patent/HRP20211926T1/hr unknown
- 2015-02-20 BR BR112016019525-6A patent/BR112016019525B1/pt not_active IP Right Cessation
- 2015-02-20 PT PT15708341T patent/PT3110438T/pt unknown
- 2015-02-20 LT LTEP15708341.1T patent/LT3110438T/lt unknown
- 2015-02-20 EA EA201691611A patent/EA034352B1/ru not_active IP Right Cessation
- 2015-02-20 WO PCT/IB2015/051308 patent/WO2015125118A1/en not_active Ceased
- 2015-02-20 SM SM20190166T patent/SMT201900166T1/it unknown
- 2015-02-20 ME MEP-2019-54A patent/ME03335B/me unknown
- 2015-02-20 JP JP2016570199A patent/JP6585085B2/ja not_active Expired - Fee Related
- 2015-02-20 LT LTEP18211544.4T patent/LT3498292T/lt unknown
- 2015-02-20 SI SI201530667T patent/SI3110438T1/sl unknown
- 2015-02-20 CN CN202010194047.1A patent/CN111499701A/zh active Pending
- 2015-02-20 CN CN201580010155.6A patent/CN106061995A/zh active Pending
- 2015-02-20 BE BE20155094A patent/BE1022345A9/fr not_active IP Right Cessation
- 2015-02-20 EP EP15708341.1A patent/EP3110438B1/en active Active
- 2015-02-20 ES ES18211544T patent/ES2899300T3/es active Active
- 2015-02-20 PL PL18211544T patent/PL3498292T3/pl unknown
- 2015-02-20 AU AU2015220369A patent/AU2015220369B2/en not_active Ceased
- 2015-02-20 HU HUE18211544A patent/HUE057505T2/hu unknown
- 2015-02-20 MX MX2016010954A patent/MX376079B/es active IP Right Grant
- 2015-02-20 CA CA2939862A patent/CA2939862C/en active Active
- 2015-02-20 RS RS20190297A patent/RS58451B1/sr unknown
- 2015-02-20 SI SI201531759T patent/SI3498292T1/sl unknown
- 2015-02-20 HR HRP20190412TT patent/HRP20190412T1/hr unknown
- 2015-02-20 PT PT182115444T patent/PT3498292T/pt unknown
- 2015-02-20 PL PL15708341T patent/PL3110438T3/pl unknown
- 2015-02-20 DK DK15708341.1T patent/DK3110438T3/en active
- 2015-02-20 SM SM20210728T patent/SMT202100728T1/it unknown
- 2015-02-20 KR KR1020167022954A patent/KR102515835B1/ko active Active
- 2015-02-20 RS RS20211446A patent/RS62592B1/sr unknown
- 2015-02-20 ES ES15708341T patent/ES2715674T3/es active Active
- 2015-02-20 SG SG11201606272PA patent/SG11201606272PA/en unknown
- 2015-02-20 DK DK18211544.4T patent/DK3498292T3/da active
- 2015-02-20 UY UY0001036006A patent/UY36006A/es not_active Application Discontinuation
- 2015-02-20 EP EP18211544.4A patent/EP3498292B1/en active Active
- 2015-02-20 HU HUE15708341A patent/HUE042054T2/hu unknown
- 2015-02-20 US US15/119,220 patent/US10040832B2/en active Active
-
2016
- 2016-07-28 IL IL246994A patent/IL246994B/en active IP Right Grant
-
2018
- 2018-06-29 US US16/023,164 patent/US10745449B2/en active Active
-
2019
- 2019-03-14 CY CY20191100307T patent/CY1121535T1/el unknown
-
2020
- 2020-06-29 US US16/914,750 patent/US10947280B2/en active Active
-
2021
- 2021-11-30 CY CY20211101038T patent/CY1124979T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017507181A5 (enExample) | ||
| JP2012126742A5 (enExample) | ||
| ES2563646T3 (es) | Composiciones y métodos relacionados con variantes de la proteína A (SpA) | |
| CN106659777A8 (zh) | 免疫原性组合产品 | |
| HRP20200466T1 (hr) | Fuzijski proteini i kombinacijska cjepiva | |
| HRP20211926T1 (hr) | Konstrukti proteina uspa2 i njihova upotreba | |
| JP2014530010A5 (enExample) | ||
| JP2017048194A5 (enExample) | ||
| JP2012000112A5 (enExample) | ||
| JP2012115277A5 (enExample) | ||
| JP2008525033A5 (enExample) | ||
| JP2010273685A5 (enExample) | ||
| JP2012095652A5 (enExample) | ||
| BRPI0922867B8 (pt) | glicoproteina de fusão (f) de vírus sincicial respiratório (rsv), ácido nucleico isolado, célula hospedeira, composição de vacina e micela purificada | |
| RU2017104529A (ru) | Композиции neisseria meningitidis и способы их применения | |
| JP2013539454A5 (enExample) | ||
| EP3266464A3 (en) | Yeast-based therapeutic for chronic hepatitis b infection | |
| JP2014051497A5 (enExample) | ||
| JP2012082206A5 (enExample) | ||
| JP2013532644A5 (enExample) | ||
| JP2016514713A5 (enExample) | ||
| JP2015533791A5 (enExample) | ||
| JP2016508503A5 (enExample) | ||
| WO2011094357A3 (en) | Repiratory virus epitopes templated into double stranded coiled -coils and use thereof in immunization | |
| JP2015536312A5 (enExample) |